Therapeutic drug monitoring shows promise for infliximab maintenance: study

Results from the NOR-DRUM B study suggest a proactive approach improves chances of achieving sustained disease control

Proactively monitoring serum drug levels and antidrug antibodies in patients undergoing infliximab maintenance therapy leads to better outcomes, new research suggests.

The findings, published in JAMA, suggest that therapeutic drug monitoring (TDM) — which involves individually tailoring biologic therapy to maximise drug efficacy and safety — could be preferable to standard care in those with immune-mediated inflammatory diseases.

Researchers behind the Norwegian Drug Monitoring (NOR-DRUM) B study say the